



ChineseInvestors.com Inc.

Ticker: (OTCQB: CIIX)

Corporate Profile

Page 1 of 2

as of November 27, 2018

Sector: Media / Internet

Industry: Communication Services/Retail

Website: www.ChineseFN.com

Background and History

ChineseInvestors.com, Inc. ("CIIX" or "the Company"), founded in 1999, is headquartered in San Gabriel, California, with offices in New York City, Richmond (Vancouver) BC, and Shanghai, China. The Company focuses on media services geared toward trading and investing in stocks and currencies and investor relations services. In addition to its core business, last year the Company diversified by establishing its consumer products division focusing on hemp oil and hemp health care products.

The Company's primary product offering is the creation of real-time stock market commentary, analysis, and educational services in the Chinese language (www.ChineseFN.com). Services offered include information about U.S. publicly-traded stocks, foreign currencies, and now digital currencies, with free quotes, charts, market news, and links to investment research. CIIX also offers paid premium subscription services that include access to sample investment portfolios (for educational purposes), as well as real-time trading demonstrations.

Hemp Division Launched

In recognition of the unprecedented opportunities in the legal industrial hemp industry, in early 2017 the Company established a Consumer Division offering non-industrial hemp products. The Company registered Xi-BiDi Biotechnology Co., Ltd. ("CBD Biotechnology Co., Ltd"), a wholly-owned foreign enterprise, in the Pudong Free-Trade Area in Shanghai and appointed XiangYang Yun as CEO. The Company offers its hemp products online as well as via retail channels including its own flagship retail store. The Company also offers hemp-based health products in China and in the Chinese community in the US. Yun's initial focus is the launch of the "CBD Magic Hemp Series" skin care line which is slated to initially include four products. In April 2017, the Company also established ChineseHempOil.com, Inc., a wholly-owned U.S. subsidiary. ChineseHempOil.com, Inc. is responsible for the development and operation of the online and retail sales of non-industrial hemp-based health products in the United States via its website ChineseHempOil.com. The Company also operates a retail store deemed the "Chinese Wellness Center," in the predominantly Chinese community of San Gabriel, California, in the Los Angeles area. The Company's first CBD oil product line, "OptHemp™", a premium private label oil, manufactured in Colorado using a CO2 Extraction process, has fast become its best seller. "OptHemp" oil sits alongside the Company's other hemp-based products, such as premium hemp gummies, water soluble soft gels, and ointments. In July 2017, CBD Biotechnology Co. Ltd., officially filed a record of its first line of non-industrial hemp-infused skin care products with the China Food and Drug Administration (CFDA). Although there has been published literature by the CFDA indicating that Cannabis can legally be added to skin care products, many Chinese skin care manufacturers have not yet entered this market. By establishing a first to market strategy, the Company's skin care products are positioned to be a leader in China. Since its launch of hemp product line, the Company's revenue grew to \$2.35 million for the fiscal year ended May 31, 2018, up 41 percent year-over-year. This increase was attributable primarily to improved product sales through its ChineseHempOil.com Inc. and CBD Biotechnology Co., Ltd. subsidiaries. Because of the hemp division's substantial anticipated revenue growth, the Company announced a spin-off to unlock hidden shareholder value, and plans to return to its main focus of providing investment information and education for Chinese-speaking communities.



CIIX displays its hemp products at the Money Show



The Company recently announced a plan to spin-off of the hemp products divisions.

Key Statistics

Price 11/27/2018	0.57
52 Week High	1.58
52 Week Low	0.37
Avg. Vol (30day)	346,610
Market Cap (Interday)M	20.28
Price/Sales (TTM)	8.33
Common Shares Outstanding (M)	35.58
Conv. Preferred Shares Outstanding (M)	8.23
Float(M)	31.63
EPS(TTM)	-0.45
Beta (3Y Monthly)	1.39

Source: Yahoo Finance / OTC Markets

Recent 2018 Highlights

- November 15, 2018, the Company announced quarterly revenues of \$712,000, up 71 percent from last year. For the fiscal year ended May 31, 2018, the Company's gross operating revenues were \$2.35 million, up 41 percent year-over-year. This increase was attributable primarily to improved product sales through its ChineseHempOil.com Inc. and CBD Biotechnology Co., Ltd. subsidiaries.
- October 16, 2018, the Company announced that its subsidiary, CBD Biotechnology Co. Ltd., has entered into Alibaba Group's Tmall (NYSE: BABA), China's largest e-commerce marketplace for global and domestic brands and retailers. This will significantly expand possible sales its full line of CBD skin-care products to include Alibaba's 500 million registered customers on Taobao and Tmall.
- October 1, 2018 the Company stated its plans to launch a private brand of CBD Hemp Wine through its wholly-owned foreign enterprise CBD Biotechnology Co. Ltd ("CBD Biotech"). Given the popularity of infused wine and liquor in recent years, CBD Biotech's new hemp-infused, rice wine was developed with the hemp enthusiast in mind.
- September 14, 2018, the Company announced it will be focusing its efforts on a spin-off of its CBD subsidiaries in order to focus on its core businesses of providing financial services, including educational services for the Chinese-speaking community in North America and China.

ChineseInvestors.com Inc.

Ticker: (OTCQB: CIIX)

Page 2 of 2

Corporate Profile

as of November 27, 2018

Sector: Media / Internet

Industry: Communication Services/Retail

Website: www.ChineseFN.com

New Developments / New Products

The Company's CBD Biotechnology Co. Ltd., has recently entered into Alibaba Group's Tmall (NYSE: BABA), China's largest e-commerce marketplace for global and domestic brands and retailers which will significantly expand the Company's ability to reach Alibaba's 500 million registered customers on the Taobao and Tmall platforms. CBD Biotechnology Co. Ltd.'s new CBD skin-care product line is the first CBD skin-care product to enter Tmall. From October 15 through the end of December 2018, the Company plans to invest 2.5 million RMB in online marketing and advertising for all of its CBD skin-care product lines, which should significantly increase awareness and interest in the brand.

The Company recently announced plans to launch a CBD Hemp Wine product line. The Company will be launching its private brand, hemp-infused rice wine, through its wholly-owned subsidiary CBD Biotechnology Co. Ltd. Management believes there are tremendous long-term potential benefits of hemp and rice wine, and rapid revenue growth is anticipated.

Financial Results

During the first fiscal quarter, the Company reported \$712,000 in total revenue, up 70.7 percent from \$417,000 in the comparable quarter last year. The Company reported total annual revenues for the year ended May 31, 2018 of \$2.35 million, up 41 percent from the previous year of \$1.67 million. This increase was primarily attributable to increased product sales of its new retail and online product line "OptHemp" in the US; and a variety of Hemp infused products in China. The Company has increased revenue from its various consulting and investor relations services. The Company reported a net loss of \$7.4 million for the year ended May 31, 2018 vs. \$3.3 million net loss in the previous year. Loss per share improved to (\$.58) from (\$.86). On September 24, 2018 the Company announced it will be focusing on the "spin-off" of the CBD subsidiary side of its business, in order to concentrate on its core business. The Company raised \$8.6 million dollars in the last fiscal year and first quarter of the current year, through the issuance of Series D preferred stock. The Company improved its balance sheet by growing total assets to \$5.9 million as of August 31, 2018, and converted a substantial number of preferred shares (multiple series) into common stock, thereby increasing its common share count to 35.58 million. Management anticipates another solid year of revenue growth.



The Company's New CBD infused Wine

Corporate Contact Information

ChineseInvestors.com Inc.

Warren Wang, CEO
 Alan Klitenic, Investor Relations
 (214) 636-2548
 227 W. Valley Blvd. Suite 208 A
 San Gabriel, CA 91776
 Email: warrenwang@chinesefn.com
 Headquarters: (888) 789-1670

www.ChineseInvestors.com
www.ChineseFN.com
www.ChineseCBDoil.com
www.ChineseHempOil.com
www.bta168.io



Income Statement				Balance Sheet				Cash Flow Statement			
	FY 5/31/17	FY 5/31/18	QTR 8/31/18		FY 5/31/17	FY 5/31/18	QTR 8/31/18		FY 5/31/17	FY 5/31/18	QTR 8/31/18
Revenue	\$ 1,668	2,353	712	Cash	\$ 1,771	1,390	2,998	Operating Cash Flow	(4,589)	(7,349)	(2,215)
Operating Loss	\$ (4,915)	(7,215)	(1,959)	Total Assets	\$ 3,172	3,676	5,988	Investing Cash Flow	1,412	(94)	(87)
Net Loss	\$ (3,337)	(7,406)	(1,460)	Total Liabilities	\$ 1,781	2,751	4,799	Financing Cash Flow	4,750	7,072	3,921
Loss Per Share	\$ (0.86)	(0.58)	(0.06)	Total Shareholder's Equity	\$ 1,391	926	1,189	Cash at end of period	1,771	1,390	2,998

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. The featured company will pay a fee of \$4500 in cash to Alan Stone & Company LLC for preparation and distribution of this updated profile, including other potential fees associated with various consulting and investor relation services. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.